Thus, mechanistically, elemene and gefitinib combination therapy inhibits EZH2 and PD-L1 levels and the cancer-stem phenotype, reverses the mesenchymal phenotype, and inhibits their ball-forming ability, thereby inhibiting tumor development in xenograft mice [66]. Here, EZH2 is linked to cancer.